Joe Victor currently serves as RareCyte President & CEO and has been a Venture Partner/Venture Advisor with 5AM Ventures since 2016. Prior to joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify and develop innovative technologies in the Life Sciences research tools markets. Prior to Startide, Mr. Victor served as CEO of DVS Sciences (acquired by Fluidigm Inc.) and Applied Precision Inc. (acquired by GE Healthcare). He currently serves on the Board of RareCyte and previously served on the Board of Precision Nanosystems (acquired by Danaher) and Purigen Biosystems (acquired by Bionano Genomics). Mr. Victor previously held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.
Ron brings a wealth of corporate leadership and technical experience to RareCyte. Prior to founding RareCyte, he was a founder and CEO at Applied Precision, Inc. (API). API initially specialized in semi-conductors. The company eventually spun off this division and began creating innovative imaging solutions for life sciences. Ron was instrumental in launching the popular DeltaVision line of microscopes, including the DeltaVision Elite and DeltaVision OMX, one of the first super-resolution imaging systems on the market. The company was sold to GE Life Sciences in 2011. His professional experience spans decades and he holds several patents.
Prior to founding 5AM in 2002, Andy was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously, Andy was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Biodesy, Bird Rock Bio, Cleave, DVS (acquired by Fluidigm), Escient, Flexion (NASDAQ: FLXN), Ikaria (acquired by Mallinckrodt and spun-out Bellerophon (NASDAQ: BLPH), Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Novome, Panomics (acquired by Affymetrix), Pear Therapeutics, Precision NanoSystems, Purigen, Synosia (acquired by Biotie), TMRW, and Viveve (NASDAQ: VIVE). Andy also serves on the Boards of Trustees of the California Academy of Sciences, Davidson College and the National Venture Capital Association (NVCA). Andy received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of its 1992 Final Four soccer team. Andy is based in 5AM’s San Francisco, CA office.
Jan founded Arboretum Ventures on the premise that innovation is key to delivering value in healthcare, a principle she developed working in the medical device industry for over two decades. Her investments focus on promising medical technologies that enable meaningful healthcare system savings while maintain great clinical outcomes. Jan has led and held board seats in more than a dozen investments across five funds including notable exits with HandyLab, Esperion (Nasdaq: ESPR), CardioMEMS, nVision, NxThera and NeuMoDx. Prior to co-founding Arboretum, Jan spent 20 years in entrepreneurial healthcare companies. She was previously President & Founder of Strategic Marketing Consultants advising healthcare start-ups and major medical device companies. Jan also held key management roles in marketing, clinical research, and sales for two successful medical device start-ups, Advanced Cardiovascular Systems and Devices for Vascular Intervention. Each of these companies was acquired by Eli Lilly and became the foundation for Guidant Corporation. Earlier in her career, Jan was an engineer and product manager for Procter & Gamble.
Robert Weisskoff, Partner, joined F-Prime Capital in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents.
A chemist by training, the companies that David has led as President, CEO or Chairman have produced billions of dollars in returns for investors and employees. He currently serves on the Boards of HealthQuest portfolio companies Lineagen, Castle Biosciences (CSTL) and Biotheranostics (in addition to RareCyte). As an operator, David’s successes include leading the development of some of the diagnostic industry’s most iconic products like the first yes/no color changing pregnancy test, the PSA test for prostate cancer and the rapid strep throat test, plus numerous cancer diagnostics. He served in senior executive positions at Hybritech, was EVP of Dura Pharmaceuticals, CEO of Spiros Development Corp., Corvas International and co-founder/CEO of Salmedix. Each of the products he developed succeeded because it made a large impact on the medical management of patients. He has served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Cebix Inc., Chairman of Amplimmune, Inc. (acquired by AstraZeneca), and as a Director of InterMune, Inc. (acquired by Roche), and Allylix, Inc. (acquired by Evolva). David earned his BA in chemistry from Case Western Reserve University and then his PhD from Yale University. He lives with his wife and enjoys fine wine, travel and skiing.
Daniel R. Marshak, Ph.D., is a highly experienced executive in the Life Sciences, Diagnostics, and Biopharmaceutical industries. In addition to serving on the Board of Directors for RareCyte, Dr. Marshak currently serves on the Board of Directors for the Tecan Group (SIX:TECN), InVivo Therapeutics (NASDAQ:NVIV), LifeVault Bio, and Elevian. Dr. Marshak is a steering panel member to the NIH RADx SARS-CoV-2 rapid diagnostics accelerator program and a consultant to leading Biotechnology and life sciences companies, as well as to venture capital, investment banking, and private equity firms. Dr. Marshak previously served as Senior Vice President & Chief Scientific Officer for PerkinElmer from 2006-2014, where he led global research and development functions. Prior to joining PerkinElmer, Dr. Marshak was Vice President and Chief Technology Officer, Biotechnology, for the Cambrex Corporation. Dr. Marshak previously served as Senior Vice President and Chief Technology Officer for Osiris Therapeutics, Inc. and was a Senior Staff Investigator at the Cold Spring Harbor Laboratory. Dr. Marshak received his Bachelor of Arts degree in Biochemical Sciences from Harvard University, and holds a Ph.D. in Biochemistry and Cell Biology from The Rockefeller University in New York City. He did postdoctoral work in Pharmacology at the Howard Hughes Medical Institute at Vanderbilt University School of Medicine in Nashville, Tennessee and was a Pharmacology Research Associate Training Fellow at the National Institute of Health in Bethesda, Maryland.
Steve has over 35 years of financial, legal, HR and operations experience. Steve had been providing financial consulting services to RareCyte since 2016 but formally hired on in November 2021. Prior to his hiring, Steve had been the CFO for Precision Nanosystems (PNI) which was acquired by Danaher Corporation in mid 2021. Prior to PNI, Steve had been the site leader for Applied Precision Inc. (API), a GE Healthcare company, after API was acquired by GE in May 2011. Prior to API, Steve spent 13 years at Flow International Corp (a public company at the time - FLOW) in the machine tools space. Steve held a variety of rolls including CFO at FLOW. Steve graduated with a BA from the University of Washington.
Mark has more than 30 years of experience in life sciences sales and commercial leadership in global markets. He has launched a number of new technologies and built robust sales and demand generation teams to drive sales success. He has worked with instruments, reagents, consumables and services for early stage, growth and mature companies. Mark has lead commercial teams for Bio-Techne, ATCC and Nexcelom (acquired by PerkinElmer). Most recently he was Vice President of Global Sales and Marketing at NanoTemper. Prior to that Mark worked in the pharma, medical device and diagnostics industry.
Leighton has over 30 years of experience in developing, launching and commercializing new technology platforms for global markets. His technical and management career focused on the pioneer instrumentation and assays for High Throughput Screening, High Content Screening and highly multiplexed imaging to support pharmaceutical drug discover/development and diagnostics. With an extensive career at GE Healthcare in Life Sciences and Diagnostic business units, Leighton held leadership positions in R&D, Operations and Commercial organizations, additionally leading the acquisition and integration of several high-performance imaging companies. Most recently, Leighton was the Director of Operations, Pharma Services at NeoGenomics. Leighton holds a bachelor’s degree in biological sciences from the University of West England, Bristol.
Tad has over 15 years of startup experience dedicated to creating scientific markets for novel instrumentation platforms that span basic research, drug discovery and clinical applications. Prior to joining RareCyte, Tad has held similar positions at Biodesy, Inc. and DVS Sciences, and was Director of Biology at Amnis Corporation. Tad completed his B.A. in Biochemistry from the Univ. of Texas at Austin, Ph.D. in Immunology from UT Southwestern Medical Center at Dallas, and post-doctoral training at Immunex Corp. in Seattle.
Eric earned his MD and trained in pathology at the University of Michigan. He was a research fellow at the National Cancer Institute and is certified by the American Board of Pathology. Before RareCyte he was the Medical Director of Companion Diagnostics at Ventana Medical Systems/Roche Tissue Diagnostics. Eric’s pharmaceutical experience has included discovery research, toxicology, and exploratory and late phase clinical development at Hoffmann-La Roche and Parke-Davis / Pfizer. He was a director of clinical genomics at Gene Logic and Chief Scientific Officer at Transgenomic. He has degree in chemistry from Harvard and studied music at Trinity College, Cambridge, England.
Jim Cooper has over 25 years of experience building and leading Finance and Accounting organizations. Jim’s responsibilities at RareCyte include Finance, Accounting, HR, Legal and Facilities. His industry experience includes technology, travel, manufacturing and life sciences, and he has held leadership roles in several public companies including Tableau Software, Cray Supercomputers, RealNetworks, and Getty Images. He holds a BA in Accounting from Seattle University and is a Licensed CPA.
Josh has over 20 years of experience in the life sciences with a deep knowledge of fluorescence microscopy and cancer-cell biology. In his over 10 years at RareCyte, Josh has contributed to the development and support of the complete portfolio of RareCyte’s products and holds 18 patents related to RareCyte’s technology. Prior to joining RareCyte, Josh earned his Ph.D. in Cell Biology from the University of Massachusetts Graduate School of Biomedical Sciences and his B.A. in Biology from Wheaton College in Norton, MA.
Dr. Ramirez has extensive experience in molecular biology applied to diagnostics. During his tenure at RareCyte he has driven the development and commercialization of novel technologies for detection, characterization, and isolation of rare cells in blood. Dr. Ramirez leads the R&D team who design and optimize novel rare-cell assays as liquid biopsies. Dr. Ramirez and his team bring extensive experience and knowledge on the RareCyte platform to develop new applications and novel biomarker assays to support customer research programs and global clinical trials. Dr. Ramirez holds a Ph.D. in Molecular and Cellular Biology from the University of Washington and a BS in Chemistry from the University of Guanajuato in Mexico.
Steve has over 25 years of experience leading R&D in the biology tools space, managing teams creating automated microscopy platforms for interrogating living cells, high-content screening cultures, and clinical research specimens. He responsibilities include IP and IT in addition to all system product development. Prior to joining RareCyte, Steve managed R&D teams at the Cell Analysis business of GE Healthcare, and at Applied Precision. He holds a B.S. in electrical engineering from Yale University.
Neil has over 30 years’ experience scaling global Life Sciences commercial organizations and driving adoption of advanced omics and analytical technologies. Neil has deep experience building high-performance teams, defining go-to-market strategy, and positioning innovative platforms for market leadership. Prior to RareCyte, Neil was the Chief Commercial Officer (CCO) at Curio Biosciences (acquired by Takara Bio USA), CCO at Rebus Biosystems, SVP Commercial Operations at Dovetail Genomics, VP Sales & Marketing at Biodesy, and VP Sales & Marketing at DVS Sciences (acquired by Fluidigm). Neil’s experience also includes positions of increasing responsibility at Sequenom, Millipore, Quantum Dot, and Affymetrix. Neil holds a BS in Biological Sciences from California State University Chico and completed Miller Heiman large account management and strategic selling training.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior and site usage.
